Value proposition

Target-led management of the causes of metabolic disease

Diabetes currently effects over 537 million adults worldwide, with obesity-driven Type 2 Diabetes accounting for over 90% of cases.

Dia Beta Labs build on over 30 years of high-impact research from our founding research group at Ulster University to realise the potential of next-generation therapeutics for metabolic disease.

It is our goal to impart significant and much-needed change in the management of the global diabetes/obesity crisis.

Diabetes, Peptide Development, Metabolic Disease, Obesity, and Peptide Therapeutics